Citigroup analyst Ronald Josey maintains Expedia Group (NASDAQ:EXPE) with a Neutral and lowers the price target from $118 to $102.
AstraZeneca Announced Datopotamab Deruxtecan-based Combinations Show Promising Clinical Activity in Patients With Advanced Non-small Cell Lung Cancer
Initial results from the TROPION-Lung02 Phase Ib trial showed that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy demonstrated promising clinical activity and a tolerable safety profile in patients with previously untreated or pretreated, advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.
